Molecular Partners
Molecular Partners is a biopharmaceutical company that specializes in the research, development, and commercialization of therapeutic proteins known as DARPin therapeutics. These proteins are designed to have specific binding properties and can be used in a variety of therapeutic applications, including oncology, ophthalmology, and immunology.
History[edit | edit source]
Molecular Partners was founded in 2004 by a group of scientists from the University of Zurich. The company's initial focus was on the development of DARPin therapeutics, a new class of protein therapeutics that offer several advantages over traditional antibodies.
DARPin Therapeutics[edit | edit source]
DARPin therapeutics are a new class of protein therapeutics that are based on the natural protein architecture of ankyrin repeat proteins. These proteins are characterized by their small size, high stability, and the ability to bind to a wide range of targets with high specificity and affinity.
DARPin therapeutics have several advantages over traditional antibodies. They are smaller, which allows them to penetrate tissues more effectively. They are also more stable, which means they can be stored and administered more easily. Furthermore, they can be engineered to bind to multiple targets simultaneously, which could potentially make them more effective in treating complex diseases.
Research and Development[edit | edit source]
Molecular Partners is currently developing several DARPin therapeutics for various indications. These include MP0250, a multi-DARPin therapeutic for the treatment of multiple myeloma, and MP0274, a single-DARPin therapeutic for the treatment of HER2-positive breast cancer.
The company is also exploring the potential of DARPin therapeutics in other areas, such as ophthalmology and immunology. For example, it is developing MP0112, a DARPin therapeutic for the treatment of age-related macular degeneration, and MP0310, a DARPin therapeutic for the treatment of autoimmune diseases.
See Also[edit | edit source]
- Protein therapeutics
- Ankyrin repeat proteins
- Multiple myeloma
- HER2-positive breast cancer
- Age-related macular degeneration
- Autoimmune diseases
References[edit | edit source]
 | This pharmacology-related article is a stub. You can help WikiMD by expanding it. |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
